Vertaling van "venous thromboembolism on risk of recurrence after " (Nederlands → Frans) :

Boutitie F, Pinede L, Schulman S et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participant’s data from seven trials.
Oudega R, Van Weert H, Stoffers H et al. NHG-Standaard: Diepe veneuze trombose.

G. Lowe en P. Sandercock: Prevention of venous thromboembolism after major orthopaedic surgery: is fondaparinux an advance?
G. Lowe et P. Sandercock: Prevention of venous thromboembolism after major orthopaedic surgery: is fondaparinux an advance?

(Lidegaard 2009) Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national
(Lidegaard 2009) Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous

Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone
Risk of non-fatal venous thromboembolism in women using oral contraceptives containing

(Jick 2006) Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or
(Jick 2006) Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism with oral contraceptives containing

(Lidegaard 2011) Lidegaard Ø, Hougaard L, Wessel Skovlund C et al. Risk of venous thromboembolism from use of oral contraceptives
(Lidegaard 2011) Lidegaard Ø, Hougaard L, Wessel Skovlund C et al. Risk of venous thromboembolism from use of oral

Risk of venous thromboembolism in users of oral contraceptives containing
Risk of venous thromboembolism in users of oral contraceptives

(Vasilakis-Scaramozza 2001) Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives.
(Vasilakis-Scaramozza 2001) Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or

A study in premenopausal women with hormone-sensitive, early-stage breast cancer showed the addition of Zometa to hormone therapy after surgery significantly reduced the risk of recurrence or death beyond benefits achieved with hormone therapy alone.
Une étude, portant sur des femmes préménopausées atteintes d’un cancer du sein au stade précoce, a montré que l’adjonction de Zometa à un traitement hormonal après intervention chirurgicale permettait une réduction significative du risque de récidive ou de décès, au-delà des bénéfices obtenus par la seule thérapie hormonale.